Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication in the class of immune checkpoint inhibitors. It selectively binds and blocks the programmed death-1 receptor on T cells, thereby facilitating their activation. From Wikipedia
Preclinical inhibition of a stress-response pathway curtailed macrophage-driven suppression, boosting checkpoint therapy in mice.
